NULOJIX
® (
belatacept) is a prescription medication approved to prevent transplant rejection in people receiving a kidney transplant. It is always used in combination with other anti-rejection medications. NULOJIX is only approved for use in people who are immune to a virus known as the Epstein-Barr virus (EBV).
Who Makes This Medication?
NULOJIX is manufactured by Bristol-Myers Squibb Company.
Transplant rejection occurs when the immune system, which is responsible for protecting the body from invaders, recognizes that your newly transplanted kidney is not a natural part of your body and attacks it. NULOJIX works by decreasing the activity of the immune system, so it is less able to reject the kidney.
Some general considerations to keep in mind during treatment with NULOJIX include the following:
- This medication is given as a slow injection into a vein (an intravenous, or IV, infusion). You will receive your first dose the day of your surgery, and then approximately every two to four weeks.
- A healthcare provider will administer your injection in a healthcare setting, such as a hospital or clinic. It will take approximately 30 minutes to administer each dose.
- For this drug to work properly, it must be taken as prescribed. Make sure to keep all of your appointments with your healthcare provider.
HealthSavvy Sign In
|
